Alcobra (ADHD) To Release Fourth Quarter 2013 Results And Host Investor Conference Call On Thursday, February 13, 2014
1/29/2014 8:52:18 AM
TEL AVIV, Israel, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter of 2013 and will host a corporate update conference call on Thursday, February 13, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by